Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TACE + Cocktail Regimen vs TACE + Targeted/Immunotherapy in Unresectable HCC
NCT07309419Phase 3Not yet recruiting
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Dec 2025
- Primary completion
- Jun 2030
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
01
Overview
A Phase 3 trial of thalidomide, capecitabine, compound cantharides capsule in hepatocellular carcinoma (HCC), sponsored by Zhongshan Hospital, Fudan University. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
thalidomidecapecitabinecompound cantharides capsule
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT07309419.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07309419.